Clear Harbor Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Clear Harbor Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-150	Closed	-$446	–	401
2020 Q3	$446	Buy	+150	New	+$587	﹤0.01%	777
2020 Q1	–	Sell	-100	Closed	-$375	–	356
2019 Q4	$375	Buy	+100	New	+$468	﹤0.01%	783
2019 Q1	–	Sell	-16,950	Closed	-$33K	–	252
2018 Q4	$33K	Hold	16,950	–	–	0.01%	235
2018 Q3	$54K	Sell	16,950 -5,000	-23%	-$15.7K	0.01%	248
2018 Q2	$68K	Buy	21,950 +10,650	+94%	+$32.3K	0.01%	245
2018 Q1	$27K	Buy	+11,300	New	+$37.6K	0.01%	231

Other funds holding CPRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Clear Harbor Asset Management's CPRX Position: Q4 2020 in Review

Clear Harbor Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q4 2020, closing a stake of 150 shares — an estimated $446 sold.

Clear Harbor Asset Management first reported a position in CPRX in Q1 2018 and held it in 6 quarters. The position peaked at $68K in Q2 2018. 135 funds tracked by Wall St. Rank hold CPRX as of Q4 2020.

Clear Harbor Asset Management reported no remaining Catalyst Pharmaceutical position as of Q4 2020 after selling out during the quarter.
Clear Harbor Asset Management sold 150 Catalyst Pharmaceutical shares in Q4 2020, an estimated $446.
Clear Harbor Asset Management first reported a position in Catalyst Pharmaceutical in Q1 2018 and held it in 6 quarters.
Clear Harbor Asset Management's Catalyst Pharmaceutical position peaked at $68K in Q2 2018.
135 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2020.

Based on Clear Harbor Asset Management's 13F filing for Q4 2020, filed 4 Feb 2021.